Action advice – Virbac: the market relieved by the good performance of sales

The veterinary laboratory reported half-yearly activity slightly better than anticipated. On the stock market, the title benefits.

While the clouds were accumulating over the animal health specialist, and its stock was suffering, the publication of the half-yearly turnover gave the price some breathing room. Indeed, while Virbac revised its annual targets sharply downward at the start of the month, sales in the second quarter marked a slight rebound compared to the first.

Thus, from April to June, the company achieved billings of 295.2 million euros, a decline of 1% in raw data but a comparable increase of 1.9%. This return to organic growth, after a decline of 1.3% from January to March, was enabled by the dynamics recorded in Europe (+7%) and Asia-Pacific (+4.5%). In detail, France accelerated sharply (+21.6%), and the United Kingdom also contributed significantly to this trend.

Latin America in difficulty

Conversely, the Latin America region weighed on performance, with sales down 11% over the period. Main country responsible: Chile.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top